Mar. 23 at 10:29 PM
$ONCT From Jim Breitmeyer's Linked In page:
"With the recent filing of our Form 25 and delisting, Oncternal's wind-down process progresses to the next phase. Despite the challenging biotech landscape hindering further advancement, our belief in the potential of our products remains steadfast. We were dedicated to developing ONCT-534 for hormone-resistant prostate cancer, ONCT-808 for late-stage aggressive lymphoma, and zilovertamab for CLL and lymphoma with aberrant TP-53 expression.
I extend my heartfelt gratitude to the patients and families who participated in our clinical trials, the clinical investigators and their teams, and our academic partners. However, my deepest appreciation goes to the exceptional individuals at Oncternal who have made these years truly fulfilling:"
